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Abstract
Insulin-like growth factor 1 receptor (IGF-1R) is a transmembrane receptor tyrosine kinase involved in the develop-
ment and progression of cancer whose activation strongly promotes cell growth and survival. IGF-1R exerts its
main actions through the activation of the mitogen-activated protein kinase and phosphoinositide 3-kinase path-
ways. In addition to their traditional roles, IGF-1R activation has been associated with increased radioresistance
both in vitro and in vivo, although the molecular mechanisms behind this process are still unclear. Recently, IGF-1R
has been associated to new partners as major vault proteins, BCL-2, BAX, or Ku70/80, related to radiochemo-
therapy resistance, regulation of apoptosis, and nonhomologous end-joining DNA repair. Here, we review these
novel associations of IGF-1R trying to explain the resistance to radiotherapy mediated by IGF-1R. Finally, we revised
the role of new therapies leading to block the receptor to enhance the efficacy of radiation.
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Insulin-like Growth Factor 1 Receptor: A Brief
Overview of Structure and Function
The insulin-like growth factor 1 receptor (IGF-1R) is a cell membrane
receptor widely distributed in human tissues. Its structure and func-
tions have been deeply explored during the last 20 years. The final
structure of the IGF-1R is a homodimer with two α extracellular
subunits and two β transmembrane subunits disulfide bonded [1].
The α subunit contains the ligand binding domain, whereas the β sub-
unit is formed by a transmembrane domain, an intracellular domain
with tyrosine kinase activity, and a C-terminal domain with protein
interaction functions [2]. IGF-1 binds with high affinity to IGF-1R.
The IGF-1R is also bound by IGF-2 and by insulin. The concentration
of circulating IGF-1 is mainly dependent on production by the liver,
which is tightly controlled by growth hormone (GH). The bioavailabil-
ity of the ligands is controlled by a family of IGF-binding proteins
(IGFBP1-6). The ratio between free and IGFBP-bound IGF is impor-
tant in determining the potency of the growth factor. Once the receptor
is activated by the binding of IGF-1, it triggers a signaling transduction
cascade to the cell nucleus thus modulating some cellular functions
through the regulation of transcription factors. The variety of cellular
responses mediated by IGF-1R is the result of a combination of down-
stream signaling pathways. These pathways include the mitogen-
activated protein kinase (MAPK) and phosphatidylinositol 3-kinase
(PI3K)pathways,whichmediate proliferation and cell survival (Figure 1).
The MAPK pathway is a wide cascade signaling that encompasses
a high number of protein kinases, mainly mediating the increase of
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cell proliferation and differentiation. IGF-1R links with MAPK
signaling through the activation of Src homology and collagen
(Shc) protein by phosphorylation. The activation of these proteins
is followed by a sequence of protein kinase phosphorylations through
the cytoplasm (Ras [human homolog of rat sarcoma], Raf [protein
serine/threonine kinase encoded by the raf oncogene], and MEK
[MAPK kinase kinase]), which reaches the extracellular signal–regulated
kinase 1 and 2 (ERK1 and ERK2) [3]. Nonetheless, this pathway also
seems to control apoptosis through the proto-oncogene Crk-II by a
Ras-dependent, Raf-1/MAPK–independent pathway [4].
The insulin receptor substrate 1 (IRS-1) is also activated when
IGF-1R is phosphorylated. This protein interacts with p85 (phos-
phatydilinositol-3′-kinase regulatory subunit), activating the catalytic
subunit (p110) of PI3K, which induces the production of activated
phospholipids as a downstream signal [5]. Protein kinase B (Akt) is
activated by the interaction with these phospholipids through the
3-phosphoinositide–dependent protein kinase. Akt interacts with the
complex BCL-2/BAD (B-cell leukemia protein/Bcl-associated death
promoter), inactivating BAD, causing the dissociation of the com-
plex, and thus releasing the antiapoptotic BCL-2 protein mainly
through the regulation of caspases [6]. BAD phosphorylation is
one of the major mechanisms by which IGF-1R induces antiapop-
tosis and cell survival [7].
IGF-1R activation has been associated with cell adhesion, cell motil-
ity, and tumor metastasis [8]. IGF-1R activation disrupts β-catenin/
E-cadherin complexes favoring cell detachment. Motility and migra-
tion are enhanced by cross talk between the IGF-1R, integrins, focal
adhesion kinase, and the RACK1 scaffolding protein and by Rho-A
activation, leading to actin reorganization and actin/myosin contrac-
tility [9]. IGF-1R stimulates the annexin II secretion to the extracel-
lular matrix promoting activation of plasminogen, cell adhesion, and
tumor metastasis and invasion [10,11]. It is suggested that the
mechanism by which IGF-1R interacts with annexin II is independent
of the main signaling pathways known of IGF-1R [12]. IGFs induce
the expression of matrix metalloproteinases, required for invasion, and
stimulate angiogenesis by activating endothelial nitric oxide synthase
Figure 1. Signaling pathways of IGF-1R and its related functions in the cell. The figure shows the IGF-1R receptor, its main substrates,
and the signaling pathways triggered as a consequence of its activation. Different colors encompass molecules implicated in the dif-
ferent cellular functions: blue, promotion of cell survival and antiapoptotic effect; orange, cell motility and invasion; and pink, cell
proliferation and mitogenic activity. Arrows represent activation. Note that this diagram is a simplification and some effectors could
be missing.
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and inducing expression of hypoxia-inducible factor-1α and vascular
endothelial growth factor [9].
These cellular functions are controlled not only by IGF-1R but
also by other tyrosine kinase receptors that share the same signaling
pathways than IGF-1R. This is the case of the epidermal growth
factor receptor (EGFR) widely related to cell transformation [13–15].
Because of their similar mechanisms of action, several publications
have studied the interaction between IGF-1 and EGF receptors. The
combine effect of IGF-1R and EGFR was firstly reported by Coppola
et al. in 1994 [16]. In their study, it is shown that at least in mouse
embryo fibroblasts, the presence of IGF-1R is required to promotemito-
genic and transforming effect of the EGFR. In 2000, Roudabush et al.
[17] defined a cross talk between IGF-1R and EGFR. The presence of
IGF-1R seems to have a relevant role as a mechanism of resistant to
anti-EGFR therapy [18]. These interactions between molecules must
be taken into account when planning the most appropriate treatment.
IGF-1R in Radiotherapy
The role of IGF-1R expression in cancer has been studied in depth
[19–21]. However, the implication of this protein in radiation re-
sponse remains unclear. Radiation causes the loss of structure and
function of most biologic molecules, including DNA. This loss of
structure of the DNA molecule includes nucleotide excision, single-
strand breaks (SSBs) and double-strand breaks (DSBs). The cells have
developed, along the evolution, some mechanisms to repair DNA
damages and thus increase their chance of survival; however, cells start
the process of apoptosis if the DNA damages are not repaired. Radia-
tion promotes a cellular state in which multiple DNA damages are
produced. The most important radiation-induced DNA damage is
the DSB [22]. This state is lethal to the cell if it is kept unrepaired.
However, cells can reverse this damage by two different pathways:
homologous recombination (HR) and nonhomologous end joining
(NHEJ) [23]. The NHEJ operates throughout the cell cycle, and it
is thought to be the most extensive DSB repair pathway in mammalian
cells [24]. Both HR and NHEJ lead to an increase in cell survival, but
in the second case, the nonspecific recombination usually results in a
loss of information of the damaged cells, favoring the survival of altered
phenotypes with genetic instability. Under these conditions, cells could
avoid the apoptosis (i.e., mediated by IGF-1R overexpression or altered
p53), which could favor tumor malignancy and reduced tumor re-
sponse to treatments [22].
The prognostic significance of IGF-1R in the response of cancer
cells to radiation has been evaluated in multiple studies. In mouse
embryo fibroblast, those cells without IGF-1R expression had higher
radiation-induced apoptosis, whereas the cells overexpressing IGF-1R
had this process inhibited [25]. Similar results have been reported
in other cell lines where overexpression of IGF-1R induces radio-
resistance [26]. Interestingly, physiological levels of IGF-1R are an
obligatory requirement for the establishment and maintenance of the
transformed phenotype [27]. In estrogen receptor (ER)–positive breast
cancer cell lines, the levels of the IGF-1R and IRS-1 are often elevated,
and these characteristics have been linked to increased radioresistance
and cancer recurrence [28]. In mouse melanoma cells, where IGF-1R
expression was artificially downregulated, the radiosensitivity was
higher compared with control cells [29]. These in vitro results highlight
the usefulness of IGF-1R in the clinical prognosis of cancer patients
treated with radiotherapy (Table 1). The first in vivo study on this field
was published in 1997 by Turner et al. [26]. They hypothesized that
those tumors that had recurred in the irradiated breast after lump-
ectomy would represent an especially radioresistant subgroup. The
IGF-1R protein expression levels were examined by immunohistochem-
ical technique in tumor specimens from local relapse after radiation
treatment of patients compared with matched nonrelapse control cases.
The staining IGF-1Rwas rated on a 4-point scale: 0, none; 1+, light; 2+,
moderate; 3+, heavy; and 4+, intense. A value of 2+ intensity was con-
sidered positive. IGF-1R was overexpressed in those cases with disease
recurrence after radiation therapy [26]. This first clinical finding was in
line with previous work, which demonstrated the antiapoptotic action
of this oncoprotein [30,31]. However, it is not yet clear whether the
IGF-1R–mediated effect on radiation response involves any of the
known apoptotic regulators, such as the BCL-2 family member proteins
or the CPP32 serine-cysteine proteases or if it is mediated by the inter-
action with other molecules. In 2007, Lloret et al. [32] studied the pro-
tein expression of IGF-1R in cervical cancer patients treated with
chemoradiotherapy. Tissue specimens were collected at diagnosis.
IGF-1R staining, observed in cell membrane, was semiquantitatively
scored from negative (−) to slightly (+), moderately (++), and strongly
positive (+++), considering IGF-1R overexpression of those tumors
showing moderately/strongly positive staining. IGF-1R was expressed
in 56 (93.7%) of 60 patients, and no relation was found with clinico-
pathologic variables. Complete response after treatment (the most
important prognostic factor for survival) was observed in 50 patients.
Thus, they analyzed the role of IGF-1R on long-term local control
Table 1. Published Studies Associating IGF-1R Expression and Clinical Outcome.
Reference No.
Patients
Type of Tumor Treatment Absolute
Expression (%)
Relative
Expression
LRDFS DMFS DFS OS
Turner et al., 1997 [26] 47 Breast cancer Lumpectomy and RT 43.0 High Worse (P = .004) — — —
Lloret et al., 2007 [32] 60 Cervical carcinoma RT, BT and ChT 80.0 High Worse (P = .045) ns Worse (P = .045) Worse (P = .032)
Lloret et al., 2008 [51] 60 Cervical carcinoma RT, BT and ChT 80.0 High* Worse (P = .006) Worse (P = .050) Worse (P = .006) Worse (P = .007)
Yuan et al., 2008 [33] 75 NPC Not reported 56.0 High Worse (P = .005) — — Worse (P = .005)
Peiró et al., 2009 [36] 197 Breast cancer CX and RT 51.5 High Better (P = .004) — — —
Taunk et al., 2010 [34] 345 Breast cancer CX and RT 57.0 High ns ns — Worse (P = .022)†
Lara et al., 2011 [35] 131 Oral cavity carcinoma CX and RT 45.8 High Worse (P = .016) ns Worse (P = .029) Worse (P = .009)
Henríquez-Hernández
et al., 2011 [53]
60 Cervical carcinoma RT, BT and ChT 80.0 High‡ Worse (P < .0001) Worse (P = .010) Worse (P < .0001) Worse (P < .0001)
BT indicates brachytherapy; ChT, chemotherapy; CX, surgery; DMFS, distant metastasis-free survival; DFS, disease-free survival; LRDFS, locoregional recurrence-free survival; ns, not significant; NPC,
nasopharyngeal carcinoma; OS, overall survival; RT, radiotherapy.
*Combined with MVP expression.
†Only in node-negative patients.
‡Combined with MVP/BCL-2 expression.
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and survival in complete responder patients. All of the 19 patients with
low IGF-1R tumors were free of local, distant, or death-related disease
versus 6 of the 31 patients bearing high IGF-1R tumors, concluding that
overexpression of IGF-1R correlated to a worse long-term local control
of the disease in patients who initially responded to the treatment [32].
Yuan et al. [33] reported that IGF-1R expressionmay play an important
role in the invasion, metastasis, and recurrence in patients with naso-
pharyngeal carcinoma. Tissue specimens were collected during biopsy,
before treatment. A semiquantitative scoring scheme was applied, con-
sidering both the extent and the intensity of staining: 0, completely neg-
ative; 1+, less than 25% positive tumor cells; 2+, 25% to 50% positive
tumor cells; and 3+, more than 50% positive tumor cells. The staining
intensity was expressed as 0 to 3, denoting absent, weak, moderate, or
strong reactivity. The final immunoreactive score was the product of
multiplying these two parameters. An immunoreactive score of 4 or
higher was considered as overexpression. IGF-1R overexpression was
detected in 42 (56%) of 75 tissues. Together with EGFR, IGF-1R
had increased expression in tumors with lymph node metastases, and
there was a positive correlation between protein positivity for EGFR/
IGF-1R and recurrence. There was a significantly higher 5-year survival
rate in the EGFR/IGF-1R protein–negative groups compared with the
EGFR/IGF-1Rprotein–positive groups [33]. Recently, Taunk et al. [36]
analyzed the prognostic significance of IGF-1R in a cohort of early-
stage breast cancer patients treated with breast-conserving surgery
and radiation therapy, trying to determine whether overexpression of
IGF-1R correlated to long-term outcomes, particularly local control.
Tissue specimens were collected at surgery, before chemoradiation ther-
apy. The intensity of IGF-1R staining was scored as 0 (0% of cells
immunoreactive), 1+ (1%-9% of cells immunoreactive), 2+ (10-40%
of cells immunoreactive), or 3+ (>50% of cells immunoreactive). Cases
scored with 0 and 1 were considered as a group with negative expression
levels, whereas cases scored with 2 and 3 with more than 10% of cells
staining were considered as positive. Of the 345 evaluable cases, IGF-
1R overexpression was noted in 197 cases (57%). IGF-1R expression
did not predict survival in the whole series. Nonetheless, on the subset
analysis of node-negative patients (good prognosis), tumors overexpres-
sing IGF-1R had a significant reduction in overall survival but no appar-
ent effect on local control [34]. Similar results have been recently
reported in oral cavity squamous cell carcinoma patients [35]. Tissue
specimens were collected at diagnosis. IGF-1R staining was semiquan-
titatively scored considering IGF-1R overexpression those tumors show-
ingmoderately/strongly positive staining. Of 131 patients, 101 (77.1%)
expressed IGF-1R. IGF-1R overexpression was predictive of poor clin-
ical outcome (including local disease-free survival, disease-free survival,
and cause-specific survival) in patients experiencing advanced stages of
the disease (III-IV) who were referred to postoperative radiotherapy
[35]. Only one study has reported contradictory results [36]. Tissue
specimens were collected at surgery, before chemoradiation therapy.
The IGF-1R staining was scored semiquantitatively according to the
percentage of positive tumor cells and intensity (from 0 to 3+; score,
0-300). High levels of active IGF-1R were related to better response
to treatment (lumpectomy and radiotherapy) in early breast cancer
patients negative for node, thus considering low active IGF-1R as a
bad prognosis factor for local recurrence [36]. The discrepancies may
be due to the selection of patients (incompletely described series or dif-
ferences in the treatment protocols or in the analysis strategy); neverthe-
less, the immunohistochemistry assay results may not be comparable
because different antibodies and scoring system were applied. Finally,
the gene expression level of IGF-1R was studied by Hirano et al. [37]
in 46 endometrial, 32 cervical, and 20 ovarian cancers and in 28 normal
endometrium, trying to disclose the molecular mechanisms behind
the apparent clinical association observed between IGF-1R over-
expression and radiation response. The authors agreed with the clin-
ical results, reporting overexpression of IGF-1R in cervical tumors
compared with normal tissues [37].
Molecular Pathways Involved in IGF-1R–Mediated
Radiation Resistance
Although the association between IGF-1R expression and radiation
response seems to exist, little is known about the mechanisms behind
this association. This fact could be explained in a classic way through
the involvement of IGF-1R in modulating cell proliferation or in an
alternative way through the relation of IGF-1R in modulating DNA
repair in association with other partners such as ataxia telangiectasia
mutated (ATM) or novel molecules such as major vault protein
(MVP). Nonetheless, both pathways probably participate in the
modulation of radiation response mediated by IGF-1R.
IGF-1R and Cell Proliferation
IGF-1R modulates cell proliferation through the classic and well-
known interaction with the MAPK pathway [3]. Cell proliferation
could be established by immunostaining of Ki67 protein. Ki67 is a
nuclear protein that is expressed in cycling cells; thus, it could rep-
resent a measurement of the tumor growth fraction [38] and, conse-
quently, could estimate tumor repopulation. The Ki67 index has
been evaluated in cancer patients treated with radiotherapy, looking
for a predictive assay for radiation response and prognosis. Response
to radiotherapy is determined mainly by tumor proliferation, radio-
sensitivity, and hypoxia. During conventional radiotherapy schedules
(for 5 weeks), a significant part of the daily dose per fraction is used
to control cells repopulated from the previous day [39,40], decreas-
ing tumor control probability. If tumors repopulate rapidly, this frac-
tion will be even higher, reducing the chance of durable local control
and cure. Thus, high proliferative tumors will have poor prognosis as
has been shown previously in the head and neck [40–42] or bladder
[43] cancer patients. In slowly proliferating tumors, repopulation is
not a major concern, and high doses of radiation can be administered
for longer periods, using several small fractions per day [44]. The direct
relation established between IGF-1R and cell proliferation points this
protein as relevant in the modulation of radiation resistance.
IGF-1R and DNA Repair and Apoptosis
X-rays interact with molecules of body tissue, causing ionization
and release of electrons, which cause secondary damage to adjacent
tissues including DNA through an oxygen-dependent mechanism.
The resultant damage can be either SSBs or DSBs within DNA.
DNA lesions are recognized by DNA damage cell cycle checkpoints
that lead to repair pathways. The ATM gene reveals that it encodes a
protein called ATM kinase, which is a member of the PI3K, a path-
way that plays a critical role in cell progression by promoting cell
proliferation and inhibiting apoptosis [45]. It has been identified that
ATM kinase is a central component for DNA damage checkpoint
pathway [46]. On exposure to ionizing radiation, ATM kinase is
immediately activated resulting in phosphorylation of a number of
critical agents that are involved in DNA repair, apoptosis, and cell
cycle arrest. Peretz et al. [47] reported a fundamental link between
ATM function and IGF-1R expression and suggested that reduced
expression of IGF-1R contributes to the radiosensitivity of ataxia
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telangiectasia (AT) cells. AT cells expressed low levels of IGF-1R and
were more radiosensitive than cells from apparently healthy indi-
viduals. Complementation of AT cells with ATM complementary
DNA results in increased IGF-1R promoter activity and IGF-1R
levels, which, in turn, led to increased radioresistance. Molecular
studies suggest that IGF-1R signaling can modulate the function
of ATM and support the concept of targeted IGF-1R down-regulation
as a potential treatment of radioresistant tumors [29].
Vaults are ribonucleoprotein particles with a hollow barrel-like
structure [48] and a mass of 13 MD. In mammals, it is composed of
three proteins: MVP (104 kDa), the vault poly(adenosine diphosphate-
ribose) polymerase (VPARP; 193 kDa), and telomerase-associated pro-
tein 1 (240 kDa), together with small untranslated RNA (vRNA) of
141 bases. MVP interacts with factors involved in apoptosis and cell
proliferation, inhibiting phosphatase and tensin homolog by increasing
PI3K/Akt–mediated inhibition of apoptosis through inhibition of the
proapoptotic BCL-2–associated agonist of cell death (BAD) protein
[49]. VPARP are proteins of the same family of poly-(ADP-ribose)
polymerase 1 (PARP-1), which have an important role in controlling
DNA repair and maintenance of DNA integrity [50]. An association
between IGF-1R and MVP has been reported [51]. Tumors showing
highMVP expression levels also had IGF-1R overexpression. MVP and
IGF-1R expression were related in clinical cervical tumors and confer
reduced long-term local control in patients treated with radioche-
motherapy, suggesting for the first time a strong correlation between
these two proteins [51]. The interaction between IGF-1R and MVP
is of great interest and can help explain the predictive role of these
oncoproteins in response to radiotherapy. In a study performed on
116 women with localized cervical carcinoma, Lloret et al. [52] re-
ported an inverse association between MVP and BAX, IGF-1R and
BAX, as well as a direct association between IGF-1R and BCL-2, sug-
gesting that IGF-1R could cooperate with MVP in preventing apopto-
sis by up-regulation of BCL-2 and down-regulation of BAX. The role
of BCL-2 in this scenario seems to be complex and closely related to
IGF-1R. This association has been recently explored by Henríquez-
Hernández et al. [53] in cervical carcinoma patients. Tumors overexpres-
sing IGF-1R showed increased levels of BCL-2 and MVP expression.
BCL-2 seemed to be an important factor in the prognosis of patients,
selecting a group of patients with excellent survival rates. Thus, all those
cervical cancer patients treated with radiochemotherapy who presented
low expression levels of MVP and/or IGF-1R and/or BCL-2 were alive
after more than 10 years of follow-up. An overexpression of the three
proteins is needed to develop a “bad prognosis” phenotype. Similar
results were observed for local relapse disease-free survival, distant
metastasis-free survival, and disease-free survival [53].
MVP is associated with the NHEJ through the interaction with
Ku70/80 [52]. The Ku70/80 heterodimer binds to the broken ends
of the DNA strands and joins other proteins to constitute the repair
complex. It also has a strong regulatory effect on the BCL-2/BAX
interaction. The Ku70/80 protein has been proposed as a key mod-
ulator of the apoptosis function [54,55]. Lloret et al. [52] showed
that low levels of Ku70/80 expression were inversely related to
BCL-2 expression and tumor proliferation and were directly related
to BAX and altered p53 expression. Ku70/80 activity is suppressed
by PARP-1 (part of vault complex), promoting HR over NHEJ [56].
The relationship between Ku70/80 and vault proteins has been re-
cently corroborated at the clinical level [52]. MVP and Ku70/80
expression were inversely related, suggesting that MVP may have a
role in favoring increased genetic instability by reducing DNA damage
repair by means of NHEJ and downregulating Ku70/80 expression.
Tumor progression and resistance to chemotherapy and radiotherapy
alsomay be activated through the suppression of BAX and up-regulation
of IGF-1R, resulting in increased proliferation and reduced apoptosis
caused by up-regulation of BCL-2 and overexpression of altered p53
[52]. The inhibition of the IGF-1R signaling induces radiosensitivity
through several pathways. Impaired IGF-1R function increased radio-
sensitivity by a mechanism involving the decrease in Ku-DNA binding
activity and nuclear Ku86 down-regulation. This mechanism was
considered p38 kinase dependent [57]. At the clinical level, Henríquez-
Hernández et al. [53] have recently reported, in 50 cervical cancer pa-
tients who achieved complete response to radiochemotherapy, that
Ku70/80 was significantly repressed in tumors overexpressing IGF-1R/
MVP/BCL-2. Ku seems to be a central regulator of apoptosis by inter-
acting with BAX [54] and BCL-2, which, in turn, has been shown to
suppress Ku70/80, thus inhibiting NHEJ repair [55]. IGF-1R may be
involved in this process through the phosphorylation of BAD, which,
in turn, promotes the liberation of BCL-2 or by the association with
MVP and the subsequent modulation of Ku (Figure 2). Although the
prognostic significance of IGF-1R is not entirely clear, it seems that this
oncoprotein could be a good prognostic factor in patients treated with
radiotherapy and may be a direct target to improve the radiation re-
sponse of cancer patients. IGF-1R may affect NHEJ by regulation of
Ku70/80 through the interaction with MVP. The cellular mechanisms
by which IGF-1R could affect Ku70/80 through MVP are unknown,
and this theoretical association may be considered as a new hypothesis
that could improve the knowledge about the role of IGF-1R in radiation
resistance (Figure 3).
IGF-1R Targeting in Radiotherapy Treatment
The influence of IGF-1R expression in cellular functions associated
to cell transformation and cancer development has been evaluated in
Figure 2. IGF-1R and its clinical relation to molecules involved in cell
proliferation, apoptosis, and DNA repair. (→) represents positive
correlation, whereas (–⊣) represents negative correlation [51,52].
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multiple studies, mainly focused on cancer cell lines. Most of the
studies tried to explore the effect of IGF-1R inhibition to elucidate
the possible use of IGF-1R as a target in cancer treatment [58]. At
the same time, another line of research that leads to evaluate the
implications of IGF-1R in radiation resistance was developed, trying
to develop possible strategies to enhance radiosensitivity. In 2005,
Cosaceanu et al. [59] found that, in non–small cell lung cancer
(NSCLC) cell lines, the blockade of IGF-1R in combination with
radiation had a synergistic effect on cell death and was associated
with an accumulation of cells in the G2 phase. The effect of IGF-1R
inhibition has been estimated in several studies, but few of them have
related this effect with radiation.
The mechanisms by which IGF-1R is inhibited are multiple and
are mainly based in its binding capacity. The use of inhibiting mole-
cules, analogous to IGF-1R ligands (IGF-1, IGF-2), is widespread,
and their effects are under study [60–64]. However, this strategy
has the problem of being nonspecific because these molecules can
bind to homologous receptors such as the insulin receptor (IR).
The use of anti–IGF-1R monoclonal antibodies has solved part of
this issue. The effect of the interaction between this potential therapy
and radiation response has been proven. Combined treatment with
the anti–IGF-1R monoclonal antibody A12 (ImClone Systems, Inc,
New York, NY) and radiation shows that the use of both treatments
enhances antitumor efficacy compared with each treatment alone
[65]. The same anti–IGF-1R antibody (A12) was used in head
and neck cancer cell lines. The combination of this treatment with
radiation induced apoptosis and increased necrosis [66]. Another
anti–IGF-1R antibody, CP 751,871, was evaluated in vitro and in vivo
in NSCLC cell lines. The analysis revealed that the use of CP 751,871
increased the sensitivity of NSCLC to radiation in vitro, increased the
number of apoptotic cells, and inhibited the repair of radiation-induced
DNA double-strand breaks, confirming the sensitizing effect of CP
751,871 in NSCLC to radiation [67].
The use of small interfering RNA (siRNA) to knock down the
endogenous regulation of IGF-1R is also under study. The lentivirus-
related siRNA IGF-1R inhibition in osteosarcoma cell lines reduced the
expression of IGF-1R, and consequently, their growth rates and inva-
siveness increased the apoptosis and enhanced their radiosensitivity
[68]. The same results were achieved in colon cancer cells [69]. Trans-
fection of the mammalian expression vector containing IGF-1R siRNA
was shown to reduce IGF-1R mRNA levels by up to 95%, reporting
that combining IGF-1R siRNA and radiation significantly enhances
antitumor efficacy compared with either modality alone [69].
Dual inhibition of tyrosine kinase receptors has emerged as a
method to improve the efficacy of targeted therapy. IGF-1R inhibi-
tion, in combination with the inhibition of other receptors such as
the platelet-derived growth factor receptor, increases cell death in
high-grade glioma cell line and induces radiosensitization of those
Figure 3. Main signaling pathways triggering by IGF-1R leading to RT resistance.
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more radioresistant cells [70]. More relevant is the association estab-
lished between the EGFR and IGF-1R. The EGFR and IGF-1R
pathways can communicate on multiple levels [71] and are logical
targets for molecular therapy for cancer based on their frequent over-
expression and established roles in the pathogenesis and progression
of numerous cancers. Treatment with either A12 (anti–IGF-1R
monoclonal antibody) or cetuximab (anti-EGFR monoclonal anti-
body) alone resulted in statistically significant inhibition of tumor-
associated angiogenesis, whereas the combination treatment with
A12 and cetuximab resulted in an additional inhibition of angiogen-
esis [72]. These findings have been observed in other studies that
have demonstrated reduction of angiogenesis resulting from inhibi-
tion of IGF-1R, EGFR, or both receptors simultaneously [73,74].
Conclusions
IGF-1R is a membrane receptor that controls several cell functions
such as proliferation, differentiation, cell survival (by inhibiting apop-
tosis), and cell adhesion. Overexpression of IGF-1R would make
cells enter in a state of alteration that ends in cancer transformation.
IGF-1R has been related to radioresistance not only in cell lines but
also in the clinical setting, making IGF-1R expression a suitable pre-
dictive factor for radiotherapy outcomes. The mechanisms by which
IGF-1R induces radioresistance could be related not only to increas-
ing proliferation and reduced apoptosis but also to DNA repair alter-
ation through its interaction with MVP and, indirectly, to Ku70/80
(Figure 3). These facts suggest that IGF-1R could be a good target
for combination treatments with other tyrosine kinase inhibitors,
chemotherapy, or radiotherapy [74–78].
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